Home > Newsletters > FDAnews Drug Daily Bulletin > FDA Prodded to Push Bio-Innovation; Agency Eyes ‘Science Enclaves’
FDAnews Drug Daily Bulletin
May 11, 2012 | Vol. 9 No. 94
FDA Prodded to Push Bio-Innovation; Agency Eyes ‘Science Enclaves’
To boost biopharma innovation and U.S. competition in the sector, the FDA should incentivize precompetitive industry collaborations, promote public-private partnerships and wrap up integration of its information technology (IT) systems, a new Obama administration paper states. “Integrating and analyzing [FDA clinical] data could revolutionize the development of new patient treatments and allow researchers to address fundamental scientific questions about how different patients respond to a therapy,” the White House Office of Science and Technology Policy (OSTP) said in its National Bioeconomy Blueprint.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.